$6.7 0.3 5.2%
Last Trade - 9:00pm
| Market Cap | £37.2m |
| Enterprise Value | £158.8m |
| Revenue | £120.8m |
| Position in Universe | 5176th / 6543 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 401.5 | 492.7 | 519.6 | 588.3 | 471.4 | 192.4 | 150.3 | 100.2 | -13.7% | ||
| +31.6 | -51.2 | |||||||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS). The Company also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company has a pipeline of neurological therapies addressing a range of disorders, including Parkinson's disease, migraine and MS. The Company's product candidate, CVT-301, is a self-administered inhaled formulation of levodopa.
| Last Annual | December 31st, 2019 |
| Last Interim | September 30th, 2020 |
| Incorporated | March 17, 1995 |
| Public Since | February 10, 2006 |
| No. of Shareholders: | 17 |
| No. of Employees: | 344 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | Nasdaq Composite , |
| Exchange | NASDAQ Global Select Market |
| Shares in Issue | 7,993,733 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 420 Saw Mill River Rd, ARDSLEY, 10502-2605, United States |
| Web | http://www.acorda.com |
| Phone | +1 914 3474300 |
| Contact | () |
| Auditors | Ernst & Young LLP |
As of 9:00pm, shares in Acorda Therapeutics Inc are trading at $6.7, giving the company a market capitalisation of £37.2m. This share price information is delayed by 15 minutes.
Shares in Acorda Therapeutics Inc are currently trading at $6.7 and the price has moved by -50.16% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Acorda Therapeutics Inc price has moved by -56.61% over the past year.
Of the analysts with advisory recommendations for Acorda Therapeutics Inc, there are there are currently 0 "buy" , 2 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Acorda Therapeutics Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Acorda Therapeutics Inc is scheduled to issue upcoming financial results on the following dates:
Acorda Therapeutics Inc does not currently pay a dividend.
Acorda Therapeutics Inc does not currently pay a dividend.
Acorda Therapeutics Inc does not currently pay a dividend.
To buy shares in Acorda Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Acorda Therapeutics Inc are currently trading at $6.7, giving the company a market capitalisation of £37.2m.
Here are the trading details for Acorda Therapeutics Inc:
Based on an overall assessment of its quality, value and momentum, Acorda Therapeutics Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Acorda Therapeutics Inc are currently priced at $6.7. At that level they are trading at 0.261% discount to the analyst consensus target price of 0.00.
Analysts covering Acorda Therapeutics Inc currently have a consensus Earnings Per Share (EPS) forecast of -8.608 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Acorda Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been 23.14%. At the current price of $6.7, shares in Acorda Therapeutics Inc are trading at 40.11% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Acorda Therapeutics Inc PE ratio based on its reported earnings over the past 12 months is 5.58. The shares are currently trading at $6.7.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Acorda Therapeutics Inc's management team is headed by:
Here are the top five shareholders of Acorda Therapeutics Inc based on the size of their shareholding:
